Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Sida 1 från 418 resultat
[Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron].
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Nausea and vomiting develop during surgery, radio- and/or chemotherapy of malignant diseases. Several drugs belonging to different groups of compounds have been used against them in a large scale. After listing these drugs the authors explained their results. Between January 1992 and 1993, 40
Multiple tumors; anorexia; vomiting. [melanoma].
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Reduced glutathione (GSH) production by tumour cells has been proposed as a mechanism for resistance to alkylating agents. High levels of paracetamol can deplete intracellular GSH. We conducted a phase I trial of high dose paracetamol and carmustine (BCNU) in patients with advanced malignant
Phase II trial of N-methylformamide in patients with metastatic melanoma.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Sixteen patients with metastatic melanoma were treated with N-methylformamide (NMF), a polar-planar compound with in vitro cytotoxic and differentiating properties. Sixteen patients were evaluable for toxicity and 14 for response. The initial four patients received an intravenous bolus of NMF 800
Methyl-CCNU in malignant melanoma--a divided dose schedule of administration.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Methyl-CCNU (NSC-95441) was administered to patients with malignant melanoma in a split dose schedule. Nausea and vomiting were eliminated as clinical problems during therapy. Response rate to the drug seemed somewhat lower than the average of three previously reported disease-oriented phase II
Disseminated malignant melanoma.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
A 25-year-old man had multiple asymptomatic, nodular lesions on the trunk, extremities and the face for 3 months. He also had left facial palsy with severe headache and vomiting. There were no other systemic or constitutional symptoms. Skin biopsy from a nodular lesion showed features of malignant
Treatment of metastatic malignant melanoma with cisplatin plus tamoxifen.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
A phase II study was performed to assess the efficacy and toxicity of the combination of cisplatin (CDDP) and tamoxifen (TAM) in patients with metastatic malignant melanoma (MM). A total of 31 consecutive previously untreated patients with unresectable measurable MM were given 100 mg/m2 CDDP every
Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
A phase II study of AMSA in previously treated patients with metastatic malignant melanoma was conducted. The dose schedule of AMSA was 40 mg/m2/day for 3 days repeated at 3-week intervals. Among the 30 evaluable patients, one achieved a complete response, one a partial response, and four had minor
Two cases of metastatic malignant melanoma of the lower limb treated with hyperthermic isolated limb perfusion and concomitant infusion of either carboplatin or beta-interferon.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Two cases of metastatic malignant melanoma of the lower limb who were treated successfully with hyperthermic isolated limb perfusion are reported. One patient was infused with cisdiammine (1.1-cyclobutanedicarboxylate) platinum (II) (carboplatin, Paraplatin, Bristol-Myers Squibb Company, New Jersey,
Dose escalation of dacarbazine combined with interferon alpha-2a, G-CSF and ondansetron in patients with metastatic melanoma.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
To define the activity of an individually escalated dacarbazine (DTIC) dose combined with interferon-alpha-2a (IFN), granulocyte-colony stimulating-factor (G-CSF) and ondansetron, 20 patients (pts) with metastatic melanoma were treated with DTIC, ondansetron 8 mg iv, G-CSF 300 micrograms sc and IFN
Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
OBJECTIVE
A high-dose interferon alfa (IFN-alpha) regimen as reported in E1684 was unique for the incorporation of an induction phase of maximally tolerated dosages of intravenous (IV) therapy for the initial 4 weeks. This is the only trial that has shown prolongation of overall survival and
Rapid plasma clearance and reduced rate and extent of urinary elimination of parenterally administered methotrexate as a result of severe vomiting and diarrhoea.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
A patient received 200 mg methotrexate IM as part of a treatment schedule for malignant melanoma. Severe vomiting and diarrhoea began shortly after treatment and persisted for 4 h. During this period the methotrexate renal clearance rate was 37 ml . min-1, increasing to 97 ml . min-1 when vomiting
Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
OBJECTIVE
Aggressive inpatient chemoimmunotherapy protocols for metastatic melanoma have yielded encouraging response rates but have required lengthy hospitalizations. To reduce or eliminate the need for hospitalization, we have developed an outpatient chemoimmunotherapy regimen and assessed its
Melanoma metastatic to the gallbladder and small bowel: report of a case and review of the literature.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
From post-mortem case records, the small bowel is the most frequent site of metastatic melanoma in the gastrointestinal (GI) tract, with gallbladder involvement occurring in 15% of cases. However, few cases have been documented in living patients and, when found, are associated with a poor
Synchronous cisplatin infusion during radiotherapy for the treatment of metastatic melanoma.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
In two pilot studies, 55 patients with symptomatic metastases from malignant melanoma were treated with irradiation and concurrent cisplatin. In the first group, cisplatin was given as a continuous intravenous infusion of 20 mg/m2 per day on days 1-5 and 22-26, with irradiation on days 2, 5, 9, 16,
Den mest kompletta databasen med medicinska örter som stöds av vetenskapen
- Fungerar på 55 språk
- Växtbaserade botemedel som stöds av vetenskap
- Örter igenkänning av bild
- Interaktiv GPS-karta - märka örter på plats (kommer snart)
- Läs vetenskapliga publikationer relaterade till din sökning
- Sök efter medicinska örter efter deras effekter
- Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent
Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning
